What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular diseases. Intervention: SCORE2 and SCORE2-OP. Primary outcome: 10-year cardiovascular risk assessment.

What question did this study set out to answer?

This research aims to highlight the key recommendations for preventing cardiovascular disease in clinical practice.

February 2, 2026Srce i krvni sudoviOpen Access

The key messages of the guidelines on cardiovascular disease prevention in clinical practice from the European Society of Cardiology 2021 (ESC)

View Full Paper

Ask AI

Bookmark

Key result

Guidelines emphasize SCORE2 and SCORE2-OP for personalized 10-year cardiovascular risk assessment.

Population

Individuals requiring cardiovascular disease prevention, including seemingly healthy people and those with…

Design

Review

Authors

DPDejan PetrovićUniverzitetski Klinički Centar Srbije

Discussion

Member takes

Implication

Supports SCORE2/SCORE2-OP integration into prevention workflows; extends prior ESC risk models with updated, individualized stratification.

Key Points

This research aims to highlight the key recommendations for preventing cardiovascular disease in clinical practice.
Reviewed guidelines from European Society of Cardiology 2021 on cardiovascular disease prevention.
Emphasized individual assessments and personalized therapy for patients.
Introduced risk models SCORE2 and SCORE2-OP for evaluating cardiovascular risk.
Established classifications of cardiovascular risk: low, moderate, high, or very high for patients.
Recommended a step-by-step approach for risk stratification and treatment.
Highlighted the importance of prevention at all levels in individual cases.

Structured PICO

Population

Individuals requiring cardiovascular disease prevention, including seemingly healthy people and those with proven cardiovascular disease.

Intervention

Personalized therapy and step-by-step approach to risk stratification using SCORE2 (for age <70) and SCORE2-OP (for age >70).

The 2021 ESC guidelines emphasize personalized cardiovascular risk assessment using SCORE2 and SCORE2-OP models and a step-by-step approach to prevention.

Limitations

The paper does not provide quantitative results from clinical trials; it is a review of guidelines.

Cite This Study

Dejan Petrović (2022) conducted a review in Cardiovascular diseases. SCORE2 and SCORE2-OP was evaluated on 10-year cardiovascular risk assessment. The guidelines emphasize using SCORE2 and SCORE2-OP for assessing cardiovascular risk based on individual characteristics and risk factors.

synapsesocial.com/papers/6980fe48c1c9540dea810305 https://doi.org/10.5937/siks2203070p

Topics

Cardiovascular prevention

View Full Paper

Ask AI

Bookmark

Implication

Supports SCORE2/SCORE2-OP integration into prevention workflows; extends prior ESC risk models with updated, individualized stratification.

The key messages of the guidelines on cardiovascular disease prevention in clinical practice from the European Society of Cardiology 2021 (ESC)

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

The key messages of the guidelines on cardiovascular disease prevention in clinical practice from the European Society of Cardiology 2021 (ESC)

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider